Cyclosporine Therapy for Chronic Plaque Psoriasis

Introduction to Cyclosporine Therapy

The American Academy of Dermatology recommends cyclosporine for severe chronic plaque psoriasis, achieving 50-70% PASI 75 response at 2.5-5 mg/kg/day within 8-16 weeks 1, 2, 3

The FDA approves cyclosporine for adult, nonimmunocompromised patients with severe, recalcitrant psoriasis, defined as extensive or disabling plaque disease that has failed at least one systemic therapy or where other systemic therapies are contraindicated or not tolerated 1, 2
Cyclosporine demonstrates particular efficacy in crisis situations, such as erythrodermic psoriasis, with dramatic improvement within 2-3 weeks, and generalized pustular psoriasis requiring rapid control 1, 2, 6

The rapid induction approach, starting at 5 mg/kg/day divided into two doses, is preferred for severe disease, with 65% of patients achieving clear or almost clear results after 8 weeks at this dose 1, 2, 3
The conservative escalation approach starts at 2.5-3.0 mg/kg/day divided twice daily, with gradual increases as needed after 4 weeks 3, 4

Short-term intermittent courses are strongly preferred over continuous therapy, with an optimal duration of 8-16 weeks per treatment course 1, 2, 3
The maximum FDA-approved duration is 1 year continuous treatment in the US and 2 years in non-US countries 1, 2

Baseline assessment should include blood pressure, BUN, serum creatinine, urinalysis, CBC, LFTs, lipid profile, magnesium, uric acid, potassium, and pregnancy test if applicable 1, 2, 4
Ongoing monitoring should include blood pressure, BUN, creatinine every 2 weeks for the first 3 months, and monthly thereafter, as well as monthly CBC, LFTs, lipid profile, magnesium, uric acid, potassium 1, 2, 7

Absolute contraindications include abnormal renal function, uncontrolled hypertension, active malignancy, hypersensitivity to cyclosporine, and concomitant use with PUVA, UVB, methotrexate, or other immunosuppressive agents 1, 2, 4

Nephrotoxicity is the most significant long-term risk, occurring in up to 71% of patients on long-term therapy, and should be managed by reducing the dose by 0.5-1.0 mg/kg if creatinine increases >30% from baseline 1, 2
Hypertension develops in 40-57% of patients and should be managed with calcium channel blockers, particularly isradipine, and avoiding thiazide diuretics and potassium-sparing diuretics 4

Cyclosporine is effective and generally well-tolerated in children at 2-5 mg/kg/day, with 77% of pediatric patients achieving excellent response with clearance in a mean of 4 weeks 7, 6, 8
Cyclosporine is classified as Category C in pregnancy and should be avoided unless benefits clearly outweigh risks 1, 2, 4

Intermittent short courses (2-12 weeks) rather than continuous therapy should be used to minimize cumulative toxicity, with only 8% of patients discontinuing due to adverse effects with this approach 4
Cyclosporine should not be combined with phototherapy (PUVA or UVB) due to increased photocarcinogenesis risk 1, 2, 4